Sarepta Therapeutics (SRPT) Says Exondys-51 List Price to be $300K/Year
- Top 10 News for 9/19 - 9/23: Twitter on the Auction Block; Allergan Bolsters NASH Effort; Microsoft Returns Value
- Wall Street falls as energy lags; shares post gains on week
- Rumored Forever, Twitter (TWTR) May Have Finally Put the 'For Sale' Sign Up
- Facebook (FB) Shares Under Pressure on Reports Video Ad Metrics Were Artificially Inflated
- Brookfield Infrastructure (BIP)-Led Consortium to Take Controlling Stake in Petrobras' (PBR) NTS for $5.2B
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Sarepta Therapeutics (NASDAQ: SRPT) Says Exondys-51 List Price to be $300K/Year
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sarepta Therapeutics (SRPT) Said to Price $300M at $59.75 - Feurstein
- Oshkosh Corp. (OSK) Boosts FY16 Outlook; Guides FY17 EPS Below Views
- Sarepta Therapeutics (SRPT) Plans to Offer $225M in Common Stock
Create E-mail Alert Related CategoriesCorporate News, Hot Corp. News, Momentum Movers
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!